We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-21.57%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$167M
AUM Growth
-$47.9M
Cap. Flow
+$7.45M
Cap. Flow %
4.46%
Top 10 Hldgs %
98.53%
Holding
14
New
2
Increased
–
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
EVAR
Lombard Medical, Inc.
EVAR
+$22.2M
2
EPRS
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
+$68.3K

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$8.17M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$6.51M
3
ZLCS
ZALICUS INC COM NEW
ZLCS
+$96K

Sector Composition

Rank Sector Weight
1 Healthcare 29.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RNA
1
DELISTED
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
$52.4M 31.32%
6,213,924
– –
EVAR
2
DELISTED
Lombard Medical, Inc.
EVAR
$25.6M 15.33%
+3,352,544
New +$22.2M
SUPN icon
3
Supernus Pharmaceuticals
SUPN
$2.59B
$25M 14.96%
2,879,328
-720,672
-20% -$6.51M
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$23.5M 14.07%
930,682
-310,230
-25% -$8.17M
DRNA
5
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$15M 8.99%
1,182,196
– –
AMRN
6
Amarin Corp
AMRN
$299M
$8.81M 5.27%
404,374
– –
CEMP
7
DELISTED
Cempra, Inc.
CEMP
$7.83M 4.68%
714,285
– –
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$2.69M 1.61%
291,902
– –
RGLS
9
DELISTED
Regulus Therapeutics
RGLS
$2.24M 1.34%
2,728
– –
ACHV icon
10
Achieve Life Sciences
ACHV
$659M
$1.6M 0.96%
274
– –
HPTX
11
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$1.58M 0.94%
62,500
– –
ANTH
12
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$832K 0.5%
54,749
– –
EPRS
13
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$56K 0.03%
+7,896
New +$68.3K
ZLCS
14
DELISTED
ZALICUS INC COM NEW
ZLCS
– –
-78,966
Closed -$96K

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q3 2014 Portfolio in Review

As of Q3 2014, Abingworth held 14 positions worth $167M, down 22% from $215M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Abingworth deployed $7.45M of net new capital in Q3 2014, opening 2 new positions. Its largest new stake was Lombard Medical, Inc.: 3,352,544 shares worth $25.6M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 34% a quarter earlier.

On the sell side, the largest reduction was Portola Pharmaceuticals, Inc., an estimated $8.17M trimmed.

  • Abingworth's largest Q3 2014 buy was Lombard Medical, Inc.: 3,352,544 shares worth $25.6M.
  • Abingworth's biggest Q3 2014 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $8.17M.
  • Abingworth fully exited ZALICUS INC COM NEW in Q3 2014, selling an estimated $96K.
  • Abingworth's ten largest holdings make up 99% of its $167M portfolio in Q3 2014.
  • Abingworth opened 2 new positions and closed 1 in Q3 2014.
  • Abingworth's portfolio value fell 22% quarter-over-quarter to $167M.

Based on Abingworth's 13F filing for Q3 2014, filed 14 Nov 2014.